Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
North Eastern German Society of Gynaecological Oncology
Canadian Cancer Trials Group
Clinica Universidad de Navarra, Universidad de Navarra
Fudan University
SWOG Cancer Research Network
Tempus AI